rss
Ann Rheum Dis 68:954-960 doi:10.1136/ard.2007.084459
  • Clinical and epidemiological research

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

Open Access
  1. G Wells1,
  2. J-C Becker2,
  3. J Teng2,
  4. M Dougados3,
  5. M Schiff4,
  6. J Smolen5,
  7. D Aletaha6,
  8. P L C M van Riel7
  1. 1
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada
  2. 2
    Bristol-Myers Squibb, Princeton, New Jersey, USA
  3. 3
    Paris-Descartes University, Medicine Faculty and UPRES-EA 4058, AP-HP, Cochin Hospital, Paris, France
  4. 4
    University of Colorado, Denver, Colorado, USA
  5. 5
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
  6. 6
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
  7. 7
    University Medical Centre, Nijmegen, The Netherlands
  1. Professor G Wells, Department of Epidemiology and Community Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, K1H 8M5, Canada; gawells{at}ottawaheart.ca
  • Accepted 9 April 2008
  • Published Online First 19 May 2008

Abstract

Objective: To validate and compare the definition of the Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to the definition based on erythrocyte sedimentation rate (ESR).

Methods: Data were analysed from two randomised, double-blind, placebo-controlled trials of abatacept of 6-month and 12-month duration in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) response criteria and the proportion of patients in remission (DAS28 <2.6) based on the two DAS28 definitions were examined. Trends in radiographic progression (erosion score, joint space narrowing score and total score) and physical function (Health Assessment Questionnaire Disability Index (HAQ-DI)) across the EULAR responder states (none, moderate and good) were analysed.

Results: There was general agreement in determining the EULAR responder state using both DAS28 definitions (κ = 0.80, 95% CI 0.76 to 0.83). Overall, there was 82.4% agreement on the EULAR response criteria; when disagreements occurred, the DAS28 (CRP) yielded a better EULAR response more often then DAS28 (ESR) (12.6% vs 4.9%, respectively). There was also agreement in determining remission: κ = 0.69 (95% CI 0.60 to 0.78). Radiographic progression decreased in patients treated with abatacept across EULAR states (from none to moderate to good) based on both definitions. For patients treated with placebo, the trend was not as pronounced, with radiographic scores higher for moderate vs non-responders. For physical function, similar trends were observed across the EULAR states for both DAS28 definitions.

Conclusions: The DAS28 (CRP) has been validated against radiographic progression and physical function. While the DAS28 (CRP) yielded a better EULAR response more often than the DAS28 (ESR), the validation profile was similar to the DAS28 (ESR), indicating that both measures are useful for assessing disease activity in patients with rheumatoid arthritis.

Footnotes

  • Competing interests: GW has received consultancies/speaking fees/honoraria from Bristol-Myers Squibb; J-CB is an employee of Bristol-Myers Squibb and has stock options; JT is an employee of Bristol-Myers Squibb and has stock options; MD has received consultancies/speaking fees/honoraria from Bristol-Myers Squibb, Abbott, Wyeth, Centocor and Schering Plough; MS has received consultancies/speaking fees/honoraria from Bristol-Myers Squibb and Centocor; JS has received consultancies/speaking fees/honoraria from Bristol-Myers Squibb; DA has received consultancies/speaking fees/honoraria from Bristol-Myers Squibb; PICMvR has received consultancies/speaking fees/honoraria from Bristol-Myers Squibb, Abbott, Wyeth, Novartis and Schering Plough.

  • Funding: This study is based upon clinical trial results from studies sponsored by Bristol-Myers Squibb, Princeton, New Jersey, USA. The authors had responsibility for the analysis and data interpretation, and all authors were involved in the drafting and critical revision of the article; in addition, all authors have seen and approved the final article for submission. This study was supported in part by an unrestricted research grant-in-aid from Bristol-Myers Squibb.

  • Ethics approval: Ethics approval was obtained.